Northwest Quadrant Wealth Management LLC cut its holdings in Pfizer Inc. (NYSE:PFE) by 11.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,733 shares of the biopharmaceutical company’s stock after selling 888 shares during the quarter. Northwest Quadrant Wealth Management LLC’s holdings in Pfizer were worth $262,000 as of its most recent SEC filing.
Several other institutional investors have also modified their holdings of PFE. 1 North Wealth Services LLC bought a new stake in Pfizer in the 3rd quarter worth about $29,000. Salomon & Ludwin LLC lifted its stake in Pfizer by 362.7% during the 3rd quarter. Salomon & Ludwin LLC now owns 893 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 700 shares during the period. Bourgeon Capital Management LLC bought a new position in Pfizer during the 3rd quarter valued at about $32,000. B & T Capital Management DBA Alpha Capital Management purchased a new stake in shares of Pfizer during the 3rd quarter valued at about $36,000. Finally, Sageworth Trust Co purchased a new stake in shares of Pfizer during the 3rd quarter valued at about $44,000. Institutional investors own 70.22% of the company’s stock.
Several equities analysts have recently weighed in on the stock. Royal Bank of Canada assumed coverage on shares of Pfizer in a research note on Monday, January 6th. They issued an “outperform” rating and a $46.00 price objective on the stock. ValuEngine raised shares of Pfizer from a “sell” rating to a “hold” rating in a report on Wednesday, October 2nd. Bank of America assumed coverage on shares of Pfizer in a research report on Wednesday, October 16th. They set a “neutral” rating and a $37.00 target price for the company. Zacks Investment Research raised shares of Pfizer from a “sell” rating to a “strong-buy” rating and set a $38.00 target price for the company in a report on Tuesday, October 1st. Finally, JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Pfizer in a research report on Tuesday, October 29th. Nine equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. Pfizer has a consensus rating of “Hold” and an average target price of $43.41.
Shares of NYSE:PFE opened at $40.34 on Wednesday. The stock has a 50 day moving average of $39.14 and a 200 day moving average of $38.09. The company has a market cap of $224.19 billion, a PE ratio of 14.10, a price-to-earnings-growth ratio of 4.24 and a beta of 0.65. The company has a current ratio of 0.90, a quick ratio of 0.68 and a debt-to-equity ratio of 0.55. Pfizer Inc. has a 12-month low of $33.97 and a 12-month high of $44.56.
Pfizer (NYSE:PFE) last released its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.62 by $0.13. Pfizer had a net margin of 30.57% and a return on equity of 28.10%. The company had revenue of $12.68 billion for the quarter, compared to analysts’ expectations of $12.37 billion. During the same quarter last year, the business earned $0.78 EPS. The firm’s revenue was down 4.6% compared to the same quarter last year. Equities research analysts predict that Pfizer Inc. will post 2.96 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 31st will be paid a $0.38 dividend. The ex-dividend date of this dividend is Thursday, January 30th. This is a boost from Pfizer’s previous quarterly dividend of $0.36. This represents a $1.52 dividend on an annualized basis and a dividend yield of 3.77%. Pfizer’s dividend payout ratio is 48.00%.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Featured Story: Most Active Stocks: Dollar Volume vs Share Volume
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.